Search

Displaying results 931 - 940 of 4344 in total
  1. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    [L34319] The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.

  2. Drug

    Natamycin

    go.drugbank.com/drugs/DB00826
    ApprovedInvestigational

    Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]

  3. Drug

    Chlorpromazine

    go.drugbank.com/drugs/DB00477
    ApprovedInvestigationalVet approved

    Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors.

    Products: Chlorprom Tab 50mg, Largactil Drops 40mg/ml
  4. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms. … While AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13).

  5. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … [L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal

    Products: SAMEXID® 50MG
  6. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections

  7. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.

  8. Drug

    Cetuximab

    go.drugbank.com/drugs/DB00002
    ApprovedInvestigational

    [A227963] Approved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic

  9. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893] … Eladocagene exuparvovec is infused directly into the brain (putamen) by bilateral intraputaminal infusion in one surgical session.

  10. Drug

    Cefepime

    go.drugbank.com/drugs/DB01413
    ApprovedInvestigational

    [A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical